This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
HIV/AIDS	CD4; HIV gp120	<p><i>In vitro</i> studies suggest bispecific antibodies targeting CD4 and gp120 could be useful for treating HIV infection. In a viral neutralization assay, bispecific mAbs engineered to recognize both CD4 and gp120 had better potency than the CD4-specific parent mAb ibalizumab. Next steps include preclinical development of the bispecific antibodies as passive immunotherapy for HIV. In 2007, TaiMed Biologics Inc. licensed ibalizumab from Genentech Inc., now a unit of Roche.</p> <p>SciBX 6(34); doi:10.1038/scibx.2013.929 Published online Sept. 5, 2013</p>	Patent pending; licensed to TaiMed Biologics	<p>Pace, C.S. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online July 22, 2013; doi:10.1073/pnas.1304985110</p> <p>Contact: David D. Ho, The Rockefeller University, New York, N.Y. e-mail: dho@adarc.org</p>